EGFR and neoplasm: Moreover, escape mutants of tumours that become resistant to EGFR inhibitor treatments were often mutants that overexpressed receptor tyrosine kinase, which mainly mediate tonic signals via the PLC signalling pathway, such as IGFR or cMET [17].